These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 33830377)

  • 1. Psychometric properties of FACIT-Fatigue in systemic lupus erythematosus: a pooled analysis of three phase 3 randomised, double-blind, parallel-group controlled studies (BLISS-SC, BLISS-52, BLISS-76).
    Rendas-Baum R; Baranwal N; Joshi AV; Park J; Kosinski M
    J Patient Rep Outcomes; 2021 Apr; 5(1):33. PubMed ID: 33830377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus.
    Rendas-Baum R; Chen WH; Gairy K; Anderson S; Henning C; Hammer A; Kosinski M
    Lupus Sci Med; 2024 May; 11(1):. PubMed ID: 38724182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in quality of life in relation to disease activity in systemic lupus erythematosus: post-hoc analysis of the BLISS-52 Trial.
    Jolly M; Annapureddy N; Arnaud L; Devilliers H
    Lupus; 2019 Dec; 28(14):1628-1639. PubMed ID: 31674267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.
    Furie R; Petri MA; Strand V; Gladman DD; Zhong ZJ; Freimuth WW;
    Lupus Sci Med; 2014; 1(1):e000031. PubMed ID: 25396065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
    RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study.
    van Vollenhoven RF; Stohl W; Furie RA; Fox NL; Groark JG; Bass D; Kurtinecz M; Pobiner BF; Eastman WJ; Gonzalez-Rivera T; Gordon D
    Lupus Sci Med; 2018; 5(1):e000288. PubMed ID: 30588323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.
    Strand V; Levy RA; Cervera R; Petri MA; Birch H; Freimuth WW; Zhong ZJ; Clarke AE;
    Ann Rheum Dis; 2014 May; 73(5):838-44. PubMed ID: 23524886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.
    Petri MA; Martin RS; Scheinberg MA; Furie RA
    Lupus; 2017 Jan; 26(1):27-37. PubMed ID: 27353505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.
    Maslen T; Bruce IN; D'Cruz D; Ianosev M; Bass DL; Wilkinson C; Roth DA
    Lupus Sci Med; 2021 Feb; 8(1):. PubMed ID: 33568389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better Health-Related Quality of Life.
    Jesus D; Henriques C; Matos A; Doria A; Inês LS
    Arthritis Care Res (Hoboken); 2024 Jun; 76(6):788-795. PubMed ID: 38258369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
    Manzi S; Sánchez-Guerrero J; Merrill JT; Furie R; Gladman D; Navarra SV; Ginzler EM; D'Cruz DP; Doria A; Cooper S; Zhong ZJ; Hough D; Freimuth W; Petri MA;
    Ann Rheum Dis; 2012 Nov; 71(11):1833-8. PubMed ID: 22550315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
    Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA;
    Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab.
    Strand V; O'Quinn S; Furie RA; Morand EF; Kalunian KC; Schwetje EG; Abreu G; Tummala R
    Lancet Rheumatol; 2022 Mar; 4(3):e198-e207. PubMed ID: 38288936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
    Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
    van Vollenhoven RF; Petri MA; Cervera R; Roth DA; Ji BN; Kleoudis CS; Zhong ZJ; Freimuth W
    Ann Rheum Dis; 2012 Aug; 71(8):1343-9. PubMed ID: 22337213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials.
    Abrahamowicz M; Esdaile JM; Ramsey-Goldman R; Simon LS; Strand V; Lipsky PE
    Arthritis Rheumatol; 2018 Sep; 70(9):1450-1458. PubMed ID: 29648686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
    Furie RA; Wallace DJ; Aranow C; Fettiplace J; Wilson B; Mistry P; Roth DA; Gordon D
    Arthritis Rheumatol; 2018 Jun; 70(6):868-877. PubMed ID: 29409143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment.
    Strand V; Berry P; Lin X; Asukai Y; Punwaney R; Ramachandran S
    Arthritis Care Res (Hoboken); 2019 Jun; 71(6):829-838. PubMed ID: 30320964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
    Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.